RGLS Regulus Therapeutics Inc. Insider Trading

Regulus pres./R&D head Klassen buys 12,000 shares at $7.99; holds 48,055 post-transaction; company recorded $-9.6M net income and zero revenue last quarter.

Klassen Preston, as President and Head of R&D, purchased 12,000 shares at $7.99, increasing his holdings by 33.3% to 48,055 shares total. The transaction occurs in a company with severe operational distress: Regulus reported zero revenue in its latest quarter and a net income of $-9,634,000.00 for its most recent full fiscal year, reflecting a -100.0% annual revenue decline year-over-year. At $7.95 current price, the stock trades near its 52-week high of $7.98, having recovered substantially from its 52-week low of $0.97 (a 90-day gain of +480.3%), yet the company remains unprofitable with no current revenue generation. This insider acquisition at peak recent valuation amid deteriorating fundamentals presents a factual tension between the open-market buy signal and the underlying business condition; investors should examine what operational developments or clinical/product catalysts justified this accumulation in a pre-revenue stage.

Director BALTIMORE DAVID bought 19,610 shares of RGLS at $1.06 on 2025-01-30; now holds 22,169 shares despite company's -$14.1M net loss and -100.0% annual revenue growth.

Director BALTIMORE DAVID purchased 19,610 shares at $1.06, increasing his holdings by 766.3% from 2,559 to 22,169 shares. The company is unprofitable with net income of -$14,062,000.00 and annual revenue growth of -100.0%, with the latest quarter showing zero revenue. The stock is currently trading at $1.00, down 65.3% from its 52-week high and down 36.7% over the past 30 days. This transaction represents a material accumulation by a director at a distressed company facing severe operational headwinds, and the filing merits examination into the context of this purchase relative to any announcements, restructuring plans, or material developments that may not yet be reflected in the public price.

CEO Joseph P Hagan bought 50.0K shares of RGLS at $1.09 on 2025-01-30; stock down 65.3% from 52-week high.

Chief Executive Officer Joseph P Hagan purchased 50,000 shares at $1.09, increasing his holdings by 23.7% to 260.8K shares post-transaction. The purchase occurs in the context of severe stock weakness: RGLS has declined 65.3% from its 52-week high of $2.88 and 36.7% over the past 30 days. The company reported zero revenue in the latest quarter and net income of $-14.1M for the full fiscal year, with annual revenue growth of -100.0%. While an open-market equity purchase by the CEO creates an observable fact in the public record, investors should evaluate this transaction against the company's operational deterioration rather than treating it in isolation from the fundamental backdrop.

Director Collier bought 4,000 RGLS shares at $1.82; holdings now 6,740 shares (+146.0%).

Director Kathryn J Collier purchased 4,000 shares of Regulus Therapeutics at $1.82 on 2024-07-25, increasing her stake by 146.0% from 2,740 to 6,740 shares. The transaction is notable for its scale relative to her prior holdings, though the absolute dollar value ($7,280.00) and company fundamentals warrant caution. Regulus reported zero revenue in its latest quarter, a net loss of $8,469,000.00, and negative annual revenue growth of -100.0%, indicating the company is in an unprofitable, early-stage or declining state. The current share price of $1.83 is 36.5% below the 52-week high of $2.88 and down 20.4% over the past 90 days, placing the purchase in a period of weakness. The transaction represents a meaningful accumulation by a board member at a depressed price level, but without additional context on company strategy or catalysts, it reflects positioning in a high-risk biotech entity with significant operational challenges.